EGFR and neoplasm: FBXW7 is one of the principal targets of miR‐223 and is well known to play a key role in carcinogenesis by facilitating the degradation of various oncoproteins, which may be involved in MDR, such as c‐Myc, Cyclin‐E, NOTCH, c‐Jun, mTOR, MCL1, etc. Several studies have earlier highlighted the role of miR‐223 in regulating tumor cell sensitivity to chemotherapeutic drugs, although its precise role in promoting tumor resistance to the effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) used in the treatment of NSCLC remains undeciphered.